Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 5/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.34 |
| ▸ | F9 | P00740 | 4/20 | 0.34 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | PLAT | P00750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7560396 | 1.00 | F11 (0.34) | F11KLKB1F9KMOMAPK14 | |
| SCHEMBL7547989 | 0.88 | MAPKAPK2 (0.33) | MAPK14 | |
| SCHEMBL13055346 | 0.88 | MAPKAPK2 (0.33) | MAPK14 | |
| SCHEMBL13054262 | 0.87 | BACE1 (0.33) | — | |
| SCHEMBL7570598 | 0.87 | BACE1 (0.33) | — | |
| SCHEMBL13054551 | 0.85 | — | — | |
| SCHEMBL7547373 | 0.85 | — | — | |
| SCHEMBL7558410 | 0.84 | BACE1 (0.36) | — | |
| SCHEMBL13054425 | 0.84 | BACE1 (0.36) | — | |
| SCHEMBL7604664 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | F11 871/4885KLKB1 2115/4885F9 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.